SCHEMBL12423655

SCHEMBL12423655

CN1CCN(Cc2cccc(Nc3nccc(-c4ccc(Br)s4)n3)c2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 6/20 0.62
JAK3 P52333 5/20 0.62
ABL1 P00519 3/20 0.51
BCR P11274 3/20 0.51
PDGFRB P09619 2/20 0.51
SRC P12931 2/20 0.51
PDGFRA P16234 2/20 0.51
SYK P43405 2/20 0.51
AIMP2 Q13155 1/20 0.48
KIT P10721 2/20 0.46
ACVR1 Q04771 1/20 0.45
PLK1 P53350 1/20 0.44
PLK4 O00444 2/20 0.44
PTK2 Q05397 1/20 0.43
GSK3B P49841 1/20 0.43
CDK2 P24941 2/20 0.43
AURKA O14965 1/20 0.43
PDPK1 O15530 1/20 0.43
CCNA2 P20248 1/20 0.43
CCNA1 P78396 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13154294 0.93 JAK2 (0.54) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL12423656 0.91 JAK2 (0.51) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL12423135 0.90 JAK2 (0.58) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL13154290 0.89 JAK2 (0.53) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL13181348 0.89 JAK2 (0.62) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL12423160 0.89 JAK2 (0.61) JAK2JAK3ABL1BCRSRC
SCHEMBL12423649 0.89 JAK2 (0.50) JAK2JAK3ABL1BCRKIT
SCHEMBL13154291 0.87 JAK2 (0.52) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL12423660 0.87 JAK2 (0.51) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL12423636 0.87 JAK2 (0.62) JAK2JAK3ABL1BCRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977481-B2 Pyrimidinyl-thiophene kinase modulators SGX PHARMACEUTICALS, INC. (US) 2011-07-12 US disclosed
US-7977481-B2 Pyrimidinyl-thiophene kinase modulators SGX PHARMACEUTICALS, INC. (US) 2011-07-12 US disclosed
US-7803806-B2 Pyrimidinyl-thiophene kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-09-28 US disclosed
US-7803806-B2 Pyrimidinyl-thiophene kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-09-28 US disclosed
US-20070117800-A1 PYRIMIDINYL-THIOPHENE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-05-24 US disclosed
US-20070117800-A1 PYRIMIDINYL-THIOPHENE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117800-A1 PYRIMIDINYL-THIOPHENE KINASE MODULATORS MAP3K20, MAP3K6, MAP4K2 JAK2 217/4885JAK3 108/4885ABL1 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.